Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of TEV-56286 in multiple system atrophy
jRCT2021240058Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing TEV-56286 with Placebo (2 arms). Primary endpoint: Change from baseline in modified Unified Multiple System Atrophy Rating Scale Part I score. Started Jun 2025; status: active, not recruiting.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on jRCT2021240058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240058.